NCT05617261 is a clinical trial of Conscious sedation in Hydrocele, sponsored by University of Manitoba.

Who is sponsoring NCT05617261?

NCT05617261 is sponsored by University of Manitoba.

What drugs are being tested in NCT05617261?

Interventions in NCT05617261: Conscious sedation.

What condition does NCT05617261 study?

NCT05617261 studies Hydrocele, Spermatocele, Varicocele, Epididymal Cyst, Testicular Biopsy, Circumcision, Frenulectomy, Penile Plication, Orchiectomy, Vasectomy Reversal, Testicular Diseases, Penile Diseases.

Is NCT05617261 still recruiting?

NCT05617261 is currently status unknown. Last updated 15 November 2022.

Last reviewed 2022-11-15 · How we verify

NCT05617261

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Patient Tolerability and Success for Penile and Scrotal Urologic Procedures Under Conscious Sedation: A Prospective Study

Status unknown Last updated 15 November 2022

What this trial tests

trial testing Conscious sedation in Hydrocele in 150 participants. Status unknown.

Timeline

13 November 2022

Primary endpoint
1 June 2023

1 June 2023

Quick facts

Lead sponsor	University of Manitoba
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	13 November 2022
Primary completion	1 June 2023
Estimated completion	1 June 2023
Sites	1 location across Canada

Drugs / interventions tested

Conscious sedation — full drug profile →

Conditions studied

Hydrocele — all drugs for Hydrocele →
Spermatocele — all drugs for Spermatocele →
Varicocele — all drugs for Varicocele →
Epididymal Cyst — all drugs for Epididymal Cyst →

Sponsor

University of Manitoba

Who can join

18 and older, male only, with Hydrocele or Spermatocele. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to evaluate patient reported outcomes and tolerability of scrotal and penile urologic procedures under the administration of minimal conscious sedation. This will be assessed at 4-6 weeks post-procedure where patients will be followed up with a questionnaire assessing how well patients tolerated the procedure and if patients would opt for conscious sedation again in a similar, future procedure. The investigators will secondarily be assessing the associated cost savings as compared to having these procedures performed under general anesthesia at a tertiary care hospital.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Utilizing Local Anesthesia Only for Penile and Scrotal Urologic Surgery: A Prospective Study on Patient Tolerability and Surgical Outcomes for a Sedation-free Option.
Bal DS, Chung D, Urichuk M, Shah J, et al · · 2024 · cited 5× · PMID 39208947 · DOI 10.1016/j.urology.2024.08.051
Poster Session 11: Sexual Health, Infertility : Monday, July 1, 2024 • 7:00–8:30
Sljivich M, Kahan D, Allan C, Djordjevic M, et al · · 2024
CUA 2023 Annual Meeting Abstracts – Poster Session 4: Transplant, Other : Saturday, June 24, 2023 • 16:10–17:40
Taka M, Sener A, Koven A, Hysi E, et al · · 2023

Verify or expand the search:

Other trials of Conscious sedation

Trials testing the same drug.

NCT06836999 — Deep Sedation in Catheter Ablation of Atrial Fibrillation · NA · not yet recruiting
NCT05550714 — Choice of Anesthesia in Microelectrode Recording Guided Deep Brain Stimulation for Parkinson's Disease · NA · recruiting

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05617261 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 15 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing